

# John Hiscott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8175166/publications.pdf>

Version: 2024-02-01

80  
papers

8,021  
citations

94433

37  
h-index

69250

77  
g-index

81  
all docs

81  
docs citations

81  
times ranked

10205  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Coronavirus pandemic â€“ 2022: Viruses, variants & vaccines. Cytokine and Growth Factor Reviews, 2022, 63, 1-9.	7.2	31
2	Type I Interferons in COVID-19 Pathogenesis. Biology, 2021, 10, 829.	2.8	32
3	Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. ACS Infectious Diseases, 2021, 7, 3034-3051.	3.8	17
4	Fighting HIV-1 Persistence: At the Crossroads of â€œShoc-K and B-Loxâ€• Pathogens, 2021, 10, 1517.	2.8	12
5	Influenza Virus Down-Modulates G6PD Expression and Activity to Induce Oxidative Stress and Promote Its Replication. Frontiers in Cellular and Infection Microbiology, 2021, 11, 804976.	3.9	31
6	Dengue Virus Targets Nrf2 for NS2B3-Mediated Degradation Leading to Enhanced Oxidative Stress and Viral Replication. Journal of Virology, 2020, 94, .	3.4	32
7	Dengue virus infection and Nrf2 regulation of oxidative stress. Current Opinion in Virology, 2020, 43, 35-40.	5.4	17
8	100 days of solitude: The spring of COVID-19 through the eyes of 15 young virologists of the INITIATE program. Virus Research, 2020, 287, 198093.	2.2	2
9	Immunometabolism pathways as the basis for innovative anti-viral strategies (INITIATE): A Marie Sklodowska-Curie innovative training network. Virus Research, 2020, 287, 198094.	2.2	2
10	SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nature Communications, 2020, 11, 4938.	12.8	272
11	Oncolytic Immunotherapy: Canâ€™t Start a Fire Without a Spark. Cytokine and Growth Factor Reviews, 2020, 56, 94-101.	7.2	9
12	Editorial overview: The challenge to defeat dengue. Current Opinion in Virology, 2020, 43, iii-v.	5.4	3
13	The global impact of the coronavirus pandemic. Cytokine and Growth Factor Reviews, 2020, 53, 1-9.	7.2	203
14	Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes. Journal of Virology, 2020, 94, .	3.4	41
15	Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators. Journal of Virology, 2019, 93, .	3.4	16
16	Alternate NF-Î³B-Independent Signaling Reactivation of Latent HIV-1 Provirus. Journal of Virology, 2019, 93, .	3.4	20
17	An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation. Cancer Immunology, Immunotherapy, 2019, 68, 1479-1492.	4.2	22
18	SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis. Journal of Virology, 2019, 93, .	3.4	18

#	ARTICLE	IF	CITATIONS
19	Cytokines 2017 in Kanazawa: Looking beyond the horizon of integrated cytokine research from the sea of Japan. <i>Cytokine and Growth Factor Reviews</i> , 2019, 50, 75-82.	7.2	1
20	Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways. <i>Trends in Immunology</i> , 2017, 38, 194-205.	6.8	249
21	Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity. <i>Molecular Therapy</i> , 2017, 25, 1900-1916.	8.2	62
22	Sphingosine 1-Phosphate Lyase Enhances the Activation of IKK $\mu$ To Promote Type I IFN-Mediated Innate Immune Responses to Influenza A Virus Infection. <i>Journal of Immunology</i> , 2017, 199, 677-687.	0.8	20
23	Evaluation of Innate Immune Gene Expression Following HDAC Inhibitor Treatment by High Throughput qPCR and PhosFlow Cytometry. <i>Methods in Molecular Biology</i> , 2017, 1510, 245-255.	0.9	1
24	Dengue Virus Immunopathogenesis: Lessons Applicable to the Emergence of Zika Virus. <i>Journal of Molecular Biology</i> , 2016, 428, 3429-3448.	4.2	33
25	Mechanisms of Zika Virus Infection and Neuropathogenesis. <i>DNA and Cell Biology</i> , 2016, 35, 367-372.	1.9	40
26	Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists. <i>Journal of Virology</i> , 2015, 89, 8011-8025.	3.4	75
27	Innate immune sensing of HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 96-102.	3.8	33
28	The intersection between viral oncolysis, drug resistance, and autophagy. <i>Biological Chemistry</i> , 2015, 396, 1269-1280.	2.5	9
29	Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. <i>MBio</i> , 2015, 6, e01316-15.	4.1	40
30	Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant. <i>Journal of Virology</i> , 2015, 89, 10612-10624.	3.4	61
31	Crosstalk between the TNF and IGF pathways enhances NF- $\kappa$ B activation and signaling in cancer cells. <i>Growth Hormone and IGF Research</i> , 2015, 25, 253-261.	1.1	20
32	HTLV-1 Tax-Mediated Inhibition of FOXO3a Activity Is Critical for the Persistence of Terminally Differentiated CD4+ T Cells. <i>PLoS Pathogens</i> , 2014, 10, e1004575.	4.7	11
33	Cellular Oxidative Stress Response Controls the Antiviral and Apoptotic Programs in Dengue Virus-Infected Dendritic Cells. <i>PLoS Pathogens</i> , 2014, 10, e1004566.	4.7	204
34	Histone Deacetylase Inhibitors Potentiate Vesicular Stomatitis Virus Oncolysis in Prostate Cancer Cells by Modulating NF- $\kappa$ B-Dependent Autophagy. <i>Journal of Virology</i> , 2014, 88, 2927-2940.	3.4	69
35	Unmasking immune sensing of retroviruses: Interplay between innate sensors and host effectors. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 657-668.	7.2	39
36	Inhibition of Dengue and Chikungunya Virus Infections by RIG-I-Mediated Type I Interferon-Independent Stimulation of the Innate Antiviral Response. <i>Journal of Virology</i> , 2014, 88, 4180-4194.	3.4	112

#	ARTICLE	IF	CITATIONS
37	Type I and type III interferon-induced immune response: It's a matter of kinetics and magnitude. <i>Hepatology</i> , 2014, 59, 1225-1228.	7.3	20
38	Coxsackievirus Cloverleaf RNA Containing a 5â€² Triphosphate Triggers an Antiviral Response via RIG-I Activation. <i>PLoS ONE</i> , 2014, 9, e95927.	2.5	16
39	Host Restriction Factor SAMHD1 Limits Human T Cell Leukemia Virus Type 1 Infection of Monocytes via STING-Mediated Apoptosis. <i>Cell Host and Microbe</i> , 2013, 14, 422-434.	11.0	158
40	BCL-2 Inhibitors Sensitize Therapy-resistant Chronic Lymphocytic Leukemia Cells to VSV Oncolysis. <i>Molecular Therapy</i> , 2013, 21, 1413-1423.	8.2	29
41	Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity. <i>PLoS Pathogens</i> , 2013, 9, e1003298.	4.7	96
42	Triptolide-Mediated Inhibition of Interferon Signaling Enhances Vesicular Stomatitis Virus-Based Oncolysis. <i>Molecular Therapy</i> , 2013, 21, 2043-2053.	8.2	22
43	Linear Ubiquitination of NEMO Negatively Regulates the Interferon Antiviral Response through Disruption of the MAVS-TRAF3 Complex. <i>Cell Host and Microbe</i> , 2012, 12, 211-222.	11.0	101
44	Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. <i>Current Opinion in Immunology</i> , 2011, 23, 564-572.	5.5	201
45	VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia. <i>Molecular Therapy</i> , 2010, 18, 2094-2103.	8.2	34
46	Oncolytic viruses and histone deacetylase inhibitorsâ€”A multi-pronged strategy to target tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 153-159.	7.2	40
47	Polo-like Kinase 1 (PLK1) Regulates Interferon (IFN) Induction by MAVS. <i>Journal of Biological Chemistry</i> , 2009, 284, 21797-21809.	3.4	81
48	The E3 Ubiquitin Ligase Triad3A Negatively Regulates the RIG-I/MAVS Signaling Pathway by Targeting TRAF3 for Degradation. <i>PLoS Pathogens</i> , 2009, 5, e1000650.	4.7	159
49	Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14981-14986.	7.1	161
50	Triggering the Innate Antiviral Response through IRF-3 Activation. <i>Journal of Biological Chemistry</i> , 2007, 282, 15325-15329.	3.4	407
51	Convergence of the NF-Î²B and IRF pathways in the regulation of the innate antiviral response. <i>Cytokine and Growth Factor Reviews</i> , 2007, 18, 483-490.	7.2	224
52	The NEMO adaptor bridges the nuclear factor-Î²B and interferon regulatory factor signaling pathways. <i>Nature Immunology</i> , 2007, 8, 592-600.	14.5	288
53	Inhibition of the interferon antiviral response by hepatitis C virus. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 49-58.	3.0	2
54	Activation of Interferon Gene Expression Through Toll-like Receptor-dependent and -independent Pathways. , 2006, , 35-72.		3

#	ARTICLE	IF	CITATIONS
55	MasterCARD: a priceless link to innate immunity. <i>Trends in Molecular Medicine</i> , 2006, 12, 53-56.	6.7	177
56	Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: Disruption by hepatitis C virus NS3-4A protease. <i>Biochemical Pharmacology</i> , 2006, 72, 1477-1484.	4.4	27
57	Activation of TBK1 and IKK Kinases by Vesicular Stomatitis Virus Infection and the Role of Viral Ribonucleoprotein in the Development of Interferon Antiviral Immunity. <i>Journal of Virology</i> , 2004, 78, 10636-10649.	3.4	164
58	Convergence of the NF- $\kappa$ B and Interferon Signaling Pathways in the Regulation of Antiviral Defense and Apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 237-248.	3.8	97
59	VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. <i>Cancer Cell</i> , 2003, 4, 263-275.	16.8	734
60	Triggering the Interferon Antiviral Response Through an IKK-Related Pathway. <i>Science</i> , 2003, 300, 1148-1151.	12.6	1,518
61	Interferon Regulatory Factors: Bridging Antiviral Defense, Growth Control, and Immunoregulation. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 3-4.	1.2	3
62	Hostile takeovers: viral appropriation of the NF- $\kappa$ B pathway. <i>Journal of Clinical Investigation</i> , 2001, 107, 143-151.	8.2	531
63	HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. <i>Oncogene</i> , 2001, 20, 800-811.	5.9	198
64	Activation of the I $\kappa$ B kinase (IKK) complex by double-stranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR. <i>Oncogene</i> , 2001, 20, 1900-1912.	5.9	61
65	The IRF-3 Transcription Factor Mediates Sendai Virus-Induced Apoptosis. <i>Journal of Virology</i> , 2000, 74, 3781-3792.	3.4	148
66	Selective DNA Binding and Association with the CREB Binding Protein Coactivator Contribute to Differential Activation of Alpha/Beta Interferon Genes by Interferon Regulatory Factors 3 and 7. <i>Molecular and Cellular Biology</i> , 2000, 20, 6342-6353.	2.3	20
67	Taxol selectively blocks microtubule dependent NF- $\kappa$ B activation by phorbol ester via inhibition of I $\kappa$ B phosphorylation and degradation. <i>Oncogene</i> , 1999, 18, 495-505.	5.9	52
68	Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2. <i>Oncogene</i> , 1999, 18, 2129-2137.	5.9	60
69	Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation. <i>Oncogene</i> , 1999, 18, 5455-5463.	5.9	19
70	A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. <i>Molecular and Cellular Biochemistry</i> , 1999, 191, 169-180.	3.1	72
71	Activation of the ubiquitin proteolytic system in murine acquired immunodeficiency syndrome affects I $\kappa$ B turnover. <i>FEBS Journal</i> , 1999, 263, 202-211.	0.2	5
72	Inducible Expression of I $\kappa$ B Repressor Mutants Interferes with NF- $\kappa$ B Activity and HIV-1 Replication in Jurkat T Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 7431-7440.	3.4	72

#	ARTICLE	IF	CITATIONS
73	Cellular and viral protein interactions regulating $\hat{I}^{\circ}B^{\hat{I}}\pm$ activity during human retrovirus infection. <i>Journal of Leukocyte Biology</i> , 1997, 62, 82-92.	3.3	19
74	Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. <i>Oncogene</i> , 1997, 15, 1425-1435.	5.9	65
75	Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon- $\hat{I}^3$ . <i>European Journal of Immunology</i> , 1997, 27, 3022-3030.	2.9	55
76	Heterodimerization and transcriptional activation in vitro by NF- $\hat{I}^B$ proteins. <i>Journal of Cellular Physiology</i> , 1992, 152, 10-18.	4.1	13
77	Non-Beta-Lactamase-Producing Penicillin-Resistant <i>Enterococcus faecium</i> in a Clinical Setting. <i>Canadian Journal of Infectious Diseases &amp; Medical Microbiology</i> , 1990, 1, 73-76.	0.3	1
78	Modulation of nuclear proto-oncogene expression and cellular growth in myeloid leukemic cells by human interferon alpha. <i>Journal of Cellular Physiology</i> , 1988, 135, 324-331.	4.1	4
79	Interferon Regulatory Factors and the Atypical IKK-Related Kinases TBK1 and IKK- $\hat{I}^{\mu}$ : Essential Players in the Innate Immune Response to RNA Virus Infection. , 0, , 51-74.		0
80	Inhibition of Glycolysis Impairs Retinoic Acid-Inducible Gene $\hat{I}^{\mu}$ -Mediated Antiviral Responses in Primary Human Dendritic Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	4